about
New and emerging HDAC inhibitors for cancer treatmentTargeting Lysine Deacetylases (KDACs) in ParasitesHDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1H-HRMAS metabolomic profile in human gliomasStatus of epigenetic chromatin modification enzymes and esophageal squamous cell carcinoma risk in northeast Indian population.Targeting Histone Deacetylases in Diseases: Where Are We?HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities.Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.Histone deacetylases and mechanisms of regulation of gene expressionAcetylation and deacetylation of Cdc25A constitutes a novel mechanism for modulating Cdc25A functions with implications for cancer.Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma.Transcriptomic changes throughout post-hatch development in Gallus gallus pituitary.Proliferative status regulates HDAC11 mRNA abundance in nontransformed fibroblasts.MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival.Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.Targeting of histone deacetylases in brain tumors.Histone deacetylase inhibitors in hematological malignancies and solid tumors.Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases.Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function.Metal-dependent Deacetylases: Cancer and Epigenetic RegulatorsHistone Modifications and Cancer.Histone deacetylases function as a novel potential therapeutic target for cancer.Anticancer Natural Compounds as Epigenetic Modulators of Gene ExpressionDisruption to schizophrenia-associated gene Fez1 in the hippocampus of HDAC11 knockout mice.Epigenetic Treatment Options in Urothelial Carcinoma.
P2860
Q27022413-E6FF7FF0-8563-4FC6-961E-448B177FDDB1Q28548415-8FE7A4F7-C34C-491F-AD1D-45E1F28339B6Q33733042-CA23D832-E780-4BB7-B851-7C1823A8E483Q35199111-7D22FB73-0711-457C-BF84-0CCA05E15DF9Q35666409-EAD35996-F8E9-429B-8FAE-E68E458BCB0EQ35821728-F18F6DC7-0931-4281-A809-DE61181BF561Q35824343-B8427A8C-B42C-4B17-9466-07501A93450DQ36214527-6AF25DBE-9909-4CE8-8B9C-C650A89899B0Q36734390-8A1BE5F7-23EA-4129-9066-24C48D88069BQ37190330-A7D513E6-43CE-49D3-AC03-01F0BE38EB70Q37404230-A51B80BC-AC47-4500-BAE0-DCB653C94D08Q37490866-E11ADE95-335C-4559-AD74-3FD7B7E3C390Q37492319-8A313B7D-0979-4D4F-A91E-C3479AD582E5Q37686989-6A7BCDFE-F0A0-4875-A151-8FEB07DFAC52Q37745480-AB9CC282-9FA5-4F96-A332-2D713E9F10F7Q38204386-7B17D502-1BF5-493E-9A52-7F08EDFD2A32Q38233117-C8F73E81-1329-44B3-9768-2F2E692A0895Q38344675-9EB2DF95-A733-457D-9151-441CDB3F4CD6Q38376048-7971BDDF-628A-4B31-A5DD-25A98227452DQ38619142-A37954DA-47C2-4B43-8BF6-28E98D170056Q38747135-5F895596-EAA4-41C8-A223-8565380BACE6Q38796064-BF41899C-5F2B-4B16-BB4D-0B02BB55924BQ38908331-0CA86A9E-6207-4DB2-B5E6-F24D99A298C8Q39214234-5D647C33-95A6-42BB-932C-0B25A8CD3BABQ41703572-91DE17B4-064E-44D4-9445-FC50294A1BA5Q50182584-F6A855A6-FA84-46E2-A0C7-BEA0B3F5D1FD
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
HDAC11 is a novel drug target in carcinomas.
@ast
HDAC11 is a novel drug target in carcinomas.
@en
HDAC11 is a novel drug target in carcinomas.
@nl
type
label
HDAC11 is a novel drug target in carcinomas.
@ast
HDAC11 is a novel drug target in carcinomas.
@en
HDAC11 is a novel drug target in carcinomas.
@nl
prefLabel
HDAC11 is a novel drug target in carcinomas.
@ast
HDAC11 is a novel drug target in carcinomas.
@en
HDAC11 is a novel drug target in carcinomas.
@nl
P2093
P2860
P356
P1476
HDAC11 is a novel drug target in carcinomas
@en
P2093
Bernard Haendler
Hedwig E Deubzer
Marco Lodrini
Marie C Schier
P2860
P304
P356
10.1002/IJC.27876
P50
P577
2012-10-25T00:00:00Z